0
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Vitamin D, Desferrioxamine and Aluminum-Induced Bone Disease in Uremic Rats

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The effect of 100 ng 1α-OH vitamin D/week alone and in combination with desferrioxamine (DFO), 150 mg/week, was evaluated in aluminum loaded uremic rats. Vitamin D (Vit D) caused an increase of A1 in muscle and a decrease in serum A1. Bone histology showed mineralization defect and an increase in bone mass, due to an increase in unmineralized bone, induced both by A1 and Vit D administration. Treatment with DFO enhanced urinary Al excretion and lowered tissue A1, without inducing major changes of static bone histology. It is concluded that in A1-loaded uremic rats Vit D can redistribute body A1 and that both Al and Vit D can cause a mineralization defect. A 6-week treatment with DFO lowers tissue A1 without changing significantly static bone parameters.

          Related collections

          Author and article information

          Journal
          NEF
          Nephron
          10.1159/issn.1660-8151
          Nephron
          S. Karger AG
          1660-8151
          2235-3186
          1989
          1989
          10 December 2008
          : 53
          : 1
          : 54-60
          Affiliations
          aDepartment of Medicine, Akademisch Ziekenhuis, bLaboratory for Pharmaceutical and Biochemical Analysis, Pharmaceutical Institute, and cDepartment of Pathology, Brugmann Ziekenhuis, Vrije Universiteit, Brussels, Belgium
          Article
          185702 Nephron 1989;53:54–60
          10.1159/000185702
          2779702
          © 1989 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 7
          Categories
          Original Paper

          Cardiovascular Medicine, Nephrology

          Desferrioxamine, Vitamin D, Aluminum, Renal osteodystrophy

          Comments

          Comment on this article